Literature DB >> 29878133

Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1.

Ayub Ali1,2, Hwee L Ng1,2, Joel N Blankson3, Dennis R Burton4,5, Robert W Buckheit3, Brian Moldt4,5, Jennifer A Fulcher1,2, F Javier Ibarrondo1,2, Peter A Anton1,2, Otto O Yang1,6,2,7.   

Abstract

A 48-year-old woman was infected with a vpr-defective human immunodeficiency virus (HIV)-1 molecular clone. Seroconversion was markedly delayed, and without treatment she had durably suppressed viremia and normal T-cell levels. Neutralizing antibody and CD8+ T-cell immune responses against HIV-1 were unremarkable. Viral sequences confirmed the source but evolved defective nef, suggesting an unknown mechanistic link to vpr. There were subtle qualitative defects in T and B cells. To our knowledge, this is the only case of human infection with a characterized defective HIV-1 molecular clone, which furthermore recapitulated live-attenuated vaccination in macaque models of HIV-1 vaccine research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29878133      PMCID： PMC6151090          DOI： 10.1093/infdis/jiy346

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Immunologic profile of highly exposed yet HIV type 1-seronegative men.

Authors:  Otto O Yang; W John Boscardin; Jose Matud; Mary Ann Hausner; Lance E Hultin; Patricia M Hultin; Roger Shih; John Ferbas; Frederick P Siegal; Michael Shodell; Gene M Shearer; Edith Grene; Mary Carrington; Steve O'Brien; Charles B Price; Roger Detels; Beth D Jamieson; Janis V Giorgi
Journal:  AIDS Res Hum Retroviruses       Date:  2002-09-20       Impact factor: 2.205

2.  HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.

Authors:  W C Goh; M E Rogel; C M Kinsey; S F Michael; P N Fultz; M A Nowak; B H Hahn; M Emerman
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection.

Authors:  W B Dyer; A F Geczy; S J Kent; L B McIntyre; S A Blasdall; J C Learmont; J S Sullivan
Journal:  AIDS       Date:  1997-11       Impact factor: 4.177

5.  Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.

Authors:  Joel N Blankson; Justin R Bailey; Seema Thayil; Hung-Chih Yang; Kara Lassen; Jun Lai; Shiv K Gandhi; Janet D Siliciano; Thomas M Williams; Robert F Siliciano
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

6.  In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus.

Authors:  B D Jamieson; J A Zack
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA.

Authors:  Betty Poon; Irvin S Y Chen
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses.

Authors:  Ayub Ali; Beth D Jamieson; Otto O Yang
Journal:  J Virol Methods       Date:  2003-06-30       Impact factor: 2.014

10.  T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols.

Authors:  Gloria Cuevas Preza; Otto O Yang; Julie Elliott; Peter A Anton; Maria T Ochoa
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240
View more
  5 in total

Review 1.  Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?

Authors:  Daniel C Rogan; Mark Connors
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-11       Impact factor: 5.071

Review 2.  Vpr Is a VIP: HIV Vpr and Infected Macrophages Promote Viral Pathogenesis.

Authors:  Jay Lubow; Kathleen L Collins
Journal:  Viruses       Date:  2020-07-27       Impact factor: 5.048

3.  HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-κB/IRF3 nuclear transport.

Authors:  Hataf Khan; Rebecca P Sumner; Jane Rasaiyaah; Choon Ping Tan; Maria Teresa Rodriguez-Plata; Chris Van Tulleken; Douglas Fink; Lorena Zuliani-Alvarez; Lucy Thorne; David Stirling; Richard Sb Milne; Greg J Towers
Journal:  Elife       Date:  2020-12-10       Impact factor: 8.140

4.  HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells.

Authors:  Ann-Kathrin Reuschl; Dejan Mesner; Maitreyi Shivkumar; Matthew V X Whelan; Laura J Pallett; José Afonso Guerra-Assunção; Rajhmun Madansein; Kaylesh J Dullabh; Alex Sigal; John P Thornhill; Carolina Herrera; Sarah Fidler; Mahdad Noursadeghi; Mala K Maini; Clare Jolly
Journal:  Cell Rep       Date:  2022-04-12       Impact factor: 9.995

5.  HIV-1 Vpr Induces Widespread Transcriptomic Changes in CD4+ T Cells Early Postinfection.

Authors:  Hélène Bauby; Christopher C Ward; Reiner Schulz; Caroline Goujon; Michael H Malim; Rupert Hugh-White; Chad M Swanson
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.